• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

应用贝叶斯等级反应模型来表征临床医生与患者对症状性不良事件分级之间的分歧领域。

Application of a Bayesian graded response model to characterize areas of disagreement between clinician and patient grading of symptomatic adverse events.

作者信息

Atkinson Thomas M, Reeve Bryce B, Dueck Amylou C, Bennett Antonia V, Mendoza Tito R, Rogak Lauren J, Basch Ethan, Li Yuelin

机构信息

Department of Psychiatry & Behavioral Sciences, Memorial Sloan Kettering Cancer Center, 641 Lexington Ave., 7th Floor, New York, NY, 10022, USA.

Duke University Medical Center, Durham, NC, USA.

出版信息

J Patient Rep Outcomes. 2018 Dec 4;2(1):56. doi: 10.1186/s41687-018-0086-x.

DOI:10.1186/s41687-018-0086-x
PMID:30515599
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6279753/
Abstract

BACKGROUND

Traditional concordance metrics have shortcomings based on dataset characteristics (e.g., multiple attributes rated, missing data); therefore it is necessary to explore supplemental approaches to quantifying agreement between independent assessments. The purpose of this methodological paper is to apply an Item Response Theory (IRT) -based framework to an existing dataset that included unidimensional clinician and multiple attribute patient ratings of symptomatic adverse events (AEs), and explore the utility of this method in patient-reported outcome (PRO) and health-related quality of life (HRQOL) research.

METHODS

Data were derived from a National Cancer Institute-sponsored study examining the validity of a measurement system (PRO-CTCAE) for patient self-reporting of AEs in cancer patients receiving treatment (N = 940). AEs included 13 multiple attribute patient-reported symptoms that had corresponding unidimensional clinician AE grades. A Bayesian IRT Model was fitted to calculate the latent grading thresholds between raters. The posterior mean values of the model-fitted item responses were calculated to represent model-based AE grades obtained from patients and clinicians.

RESULTS

Model-based AE grades showed a general pattern of clinician underestimation relative to patient-graded AEs. However, the magnitude of clinician underestimation was associated with AE severity, such that clinicians' underestimation was more pronounced for moderate/very severe model-estimated AEs, and less so with mild AEs.

CONCLUSIONS

The Bayesian IRT approach reconciles multiple symptom attributes and elaborates on the patterns of clinician-patient non-concordance beyond that provided by traditional metrics. This IRT-based technique may be used as a supplemental tool to detect and characterize nuanced differences in patient-, clinician-, and proxy-based ratings of HRQOL and patient-centered outcomes.

TRIAL REGISTRATION

ClinicalTrials.gov NCT01031641 . Registered 1 December 2009.

摘要

背景

传统的一致性指标基于数据集特征存在缺陷(例如,多个属性评分、缺失数据);因此,有必要探索补充方法来量化独立评估之间的一致性。本方法学论文的目的是将基于项目反应理论(IRT)的框架应用于一个现有数据集,该数据集包含有症状不良事件(AE)的单维临床医生评分和多属性患者评分,并探讨该方法在患者报告结局(PRO)和健康相关生活质量(HRQOL)研究中的效用。

方法

数据来自一项由美国国立癌症研究所资助的研究,该研究考察了一种测量系统(PRO-CTCAE)在接受治疗的癌症患者中对AE进行患者自我报告的有效性(N = 940)。AE包括13种多属性患者报告的症状,这些症状有相应的单维临床医生AE分级。拟合贝叶斯IRT模型以计算评分者之间的潜在分级阈值。计算模型拟合项目反应的后验均值,以代表从患者和临床医生获得的基于模型的AE分级。

结果

相对于患者分级的AE,基于模型的AE分级显示出临床医生普遍低估的模式。然而,临床医生低估的程度与AE严重程度相关,即临床医生对中度/非常严重的模型估计AE的低估更为明显,而对轻度AE的低估则较少。

结论

贝叶斯IRT方法协调了多个症状属性,并详细阐述了临床医生与患者不一致的模式,超出了传统指标所提供的范围。这种基于IRT的技术可作为一种补充工具,用于检测和描述基于患者、临床医生和代理人的HRQOL评分以及以患者为中心的结局中的细微差异。

试验注册

ClinicalTrials.gov NCT01031641。2009年12月1日注册。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3df1/6279753/d63c2cedbfd7/41687_2018_86_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3df1/6279753/d4dfd38813a3/41687_2018_86_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3df1/6279753/4e32060eadc9/41687_2018_86_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3df1/6279753/d63c2cedbfd7/41687_2018_86_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3df1/6279753/d4dfd38813a3/41687_2018_86_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3df1/6279753/4e32060eadc9/41687_2018_86_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3df1/6279753/d63c2cedbfd7/41687_2018_86_Fig3_HTML.jpg

相似文献

1
Application of a Bayesian graded response model to characterize areas of disagreement between clinician and patient grading of symptomatic adverse events.应用贝叶斯等级反应模型来表征临床医生与患者对症状性不良事件分级之间的分歧领域。
J Patient Rep Outcomes. 2018 Dec 4;2(1):56. doi: 10.1186/s41687-018-0086-x.
2
Exploring differences in adverse symptom event grading thresholds between clinicians and patients in the clinical trial setting.探索临床试验环境中临床医生与患者之间不良症状事件分级阈值的差异。
J Cancer Res Clin Oncol. 2017 Apr;143(4):735-743. doi: 10.1007/s00432-016-2335-9. Epub 2017 Jan 16.
3
Mapping child and adolescent self-reported symptom data to clinician-reported adverse event grading to improve pediatric oncology care and research.将儿童和青少年自我报告的症状数据与临床医生报告的不良事件分级进行映射,以改善儿科肿瘤学的护理和研究。
Cancer. 2020 Jan 1;126(1):140-147. doi: 10.1002/cncr.32525. Epub 2019 Sep 25.
4
Patient perspectives in adverse event reporting after vaginal apical prolapse surgery.阴道顶端脱垂手术后不良事件报告中的患者视角。
Am J Obstet Gynecol. 2024 Aug;231(2):268.e1-268.e16. doi: 10.1016/j.ajog.2024.04.043. Epub 2024 May 6.
5
Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial.从患者角度评估 III 期转移性去势抵抗性前列腺癌临床试验中的不良事件。
JAMA Oncol. 2020 Feb 1;6(2):e193332. doi: 10.1001/jamaoncol.2019.3332. Epub 2020 Feb 13.
6
Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials.I期临床试验中症状不良事件漏报。
J Natl Cancer Inst. 2021 Aug 2;113(8):980-988. doi: 10.1093/jnci/djab015.
7
Lack of Concordance in Symptomatic Adverse Event Reporting by Children, Clinicians, and Caregivers: Implications for Cancer Clinical Trials.患儿、临床医生和照护者在症状不良事件报告中的一致性缺失:对癌症临床试验的启示。
J Clin Oncol. 2022 May 20;40(15):1623-1634. doi: 10.1200/JCO.21.02669. Epub 2022 Mar 16.
8
Integrating the patient voice with clinician reports to identify a hepatocellular carcinoma-specific subset of treatment-related symptomatic adverse events.整合患者反馈与临床医生报告,以识别肝细胞癌特异性的治疗相关症状性不良事件亚组。
J Patient Rep Outcomes. 2018 Aug 22;2:35. doi: 10.1186/s41687-018-0063-4. eCollection 2017.
9
Recommended scoring approach for the pediatric patient-reported outcomes version of the Common Terminology Criteria for Adverse Events.推荐用于儿科患者报告结局的常见不良事件术语标准版本的评分方法。
Pediatr Blood Cancer. 2022 Jun;69(6):e29452. doi: 10.1002/pbc.29452. Epub 2021 Dec 6.
10
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.

引用本文的文献

1
A Comparison of Patient- and Clinician-Reported Acute Toxic Effects During Radiation Therapy for Primary Breast Cancer.原发性乳腺癌放射治疗中患者和临床医生报告的急性毒性效应比较。
Int J Radiat Oncol Biol Phys. 2022 Oct 1;114(2):301-309. doi: 10.1016/j.ijrobp.2022.05.041. Epub 2022 Jun 5.
2
Congruence of patient- and clinician-reported toxicity in women receiving chemotherapy for early breast cancer.接受化疗的早期乳腺癌女性患者报告的毒性与临床医生报告的毒性的一致性。
Cancer. 2020 Jul 1;126(13):3084-3093. doi: 10.1002/cncr.32898. Epub 2020 Apr 21.

本文引用的文献

1
What Do "None," "Mild," "Moderate," "Severe," and "Very Severe" Mean to Patients With Cancer? Content Validity of PRO-CTCAE™ Response Scales.“无”“轻度”“中度”“重度”和“极重度”对癌症患者意味着什么?PRO-CTCAE™反应量表的内容效度。
J Pain Symptom Manage. 2018 Mar;55(3):e3-e6. doi: 10.1016/j.jpainsymman.2017.10.024. Epub 2017 Nov 10.
2
Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE.对美国国立癌症研究所的PRO-CTCAE不同召回期的评估。
Clin Trials. 2017 Jun;14(3):255-263. doi: 10.1177/1740774517698645. Epub 2017 Mar 20.
3
Exploring differences in adverse symptom event grading thresholds between clinicians and patients in the clinical trial setting.
探索临床试验环境中临床医生与患者之间不良症状事件分级阈值的差异。
J Cancer Res Clin Oncol. 2017 Apr;143(4):735-743. doi: 10.1007/s00432-016-2335-9. Epub 2017 Jan 16.
4
The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review.基于临床医生的不良事件通用术语标准(CTCAE)与患者报告结局(PRO)之间的关联:一项系统评价。
Support Care Cancer. 2016 Aug;24(8):3669-76. doi: 10.1007/s00520-016-3297-9. Epub 2016 Jun 3.
5
Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).美国国立癌症研究所不良事件通用术语标准患者报告结局(PRO-CTCAE)的平板电脑、交互式语音应答系统和纸质管理方式的模式等效性与可接受性
Health Qual Life Outcomes. 2016 Feb 19;14:24. doi: 10.1186/s12955-016-0426-6.
6
Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).美国国家癌症研究所患者报告结局版通用不良事件术语标准(PRO-CTCAE)的有效性和可靠性。
JAMA Oncol. 2015 Nov;1(8):1051-9. doi: 10.1001/jamaoncol.2015.2639.
7
Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).国家癌症研究所患者报告结局版通用不良事件术语标准(PRO-CTCAE)的制定。
J Natl Cancer Inst. 2014 Sep 29;106(9). doi: 10.1093/jnci/dju244. Print 2014 Sep.
8
Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).对美国国家癌症研究所患者报告结局版通用不良事件术语标准(PRO-CTCAE)进行认知访谈。
Qual Life Res. 2014 Feb;23(1):257-69. doi: 10.1007/s11136-013-0470-1. Epub 2013 Jul 20.
9
Comparison between patient-reported and clinician-observed symptoms in oncology.肿瘤患者报告症状与临床医生观察症状的比较。
Cancer Nurs. 2013 Nov-Dec;36(6):E1-E16. doi: 10.1097/NCC.0b013e318269040f.
10
Impact of oxaliplatin-induced neuropathy: a patient perspective.奥沙利铂诱导神经病变的影响:患者视角。
Support Care Cancer. 2012 Nov;20(11):2959-67. doi: 10.1007/s00520-012-1428-5. Epub 2012 Mar 17.